In the present study, we hypothesized that the most relevant SNPs in genes encoded for MDR1, BCRP, and MPR2 could predict the outcome of CML patients treated with nilotinib. Here, ABCB1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.